Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
Go back to Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs| (NASDAQ: SANA) | Delayed: 3.15 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.15 | 52 Week High | $ | |||
| Open | $3.15 | 52 Week Low | $ | |||
| Day High | $3.15 | P/E | N/A | |||
| Day Low | $3.15 | EPS | $ | |||
| Volume | 11,488 | |||||
